Cancer Therapy
CoFactor phase IIb trial surpasses 50% enrollment milestone
Published in Drug Week, March 10th, 2006
The company announced patient recruitment has surpassed the half-way point in the CoFactor multi-national phase IIb clinical trial for metastatic colorectal cancer which was initiated in May 2005. The company also announced an update regarding its planned phase III clinical studies for CoFactor.
The first phase III study will evaluate CoFactor in the first-line treatment of metastatic colorectal cancer. The second proposed phase III study would evaluate CoFactor in a third-line setting for advanced breast cancer. CoFactor...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-03-10)
More Articles from Drug Week
- Disease Associations
Enalapril plus lercanidipine had better blood pressure response rate than enalapril and HCTZ - HIV/AIDS Therapy
Drug compound kills multiple HIV strains in in vitro lab test, researchers report - HIV/AIDS Therapy
Positive results reported from Aptivus (tipranavir) RESIST studies - Rotavirus Gastroenteritis
U.S. FDA approves Rotateq to prevent a leading cause of severe infant diarrhea - Acute Ischemic Stroke
Biopharma company to start phase IIa study with neuroprotectant Enecadin in acute ischemic stroke - Addiction Medicine
Antipsychotic drug may stop addiction to opioid painkillers - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
